ImmunoGen, Inc.
2024
$10.1B
Why
Added Elahere and antibody-drug conjugate programs in oncology.
AbbVie Inc.
BiopharmaceuticalFounded 2013- HQ today: North Chicago, Illinois
Reviewed by Swet Parvadiya
Company data updated: September 2026
Acquisitions
AbbVie Acquisitions
4
Major Deals Covered
$102.8B
Disclosed Deal Value
What are AbbVie's biggest acquisitions?
AbbVie's largest disclosed acquisition here is Allergan plc for $63B in 2020. This page covers 4 major deals from 2015 to 2024, each with its price where disclosed and the reason behind it.
- Major deals covered
- 4
- Largest deal
- Allergan plc ($63B)
- First deal
- 2015
- Most recent
- 2024
| Company | Year | Price | Purpose |
|---|---|---|---|
| Pharmacyclics, Inc. | 2015 | $21.0B | Added Imbruvica and expanded AbbVie's hematologic oncology business. |
| Allergan plc | 2020 | $63.0B | Added neuroscience, eye care, and Allergan Aesthetics products, including Botox and Juvederm. |
| ImmunoGen, Inc. | 2024 | $10.1B | Added Elahere and antibody-drug conjugate programs in oncology. |
| Cerevel Therapeutics | 2024 | $8.7B | Added clinical-stage neuroscience programs including emraclidine and tavapadon. |
- What companies has AbbVie bought?
- Major acquisitions by AbbVie documented here include Allergan plc (2020), Pharmacyclics, Inc. (2015), ImmunoGen, Inc. (2024) and Cerevel Therapeutics (2024).
- What is AbbVie's most recent acquisition?
- The most recent AbbVie acquisition documented here is ImmunoGen, Inc., in 2024, for $10.1B.
Cerevel Therapeutics
2024
$8.7B
Why
Added clinical-stage neuroscience programs including emraclidine and tavapadon.
Allergan plc
2020
$63.0B
Why
Added neuroscience, eye care, and Allergan Aesthetics products, including Botox and Juvederm.
Pharmacyclics, Inc.
2015
$21.0B
Why
Added Imbruvica and expanded AbbVie's hematologic oncology business.
AbbVie Inc.'s Growth & Acquisition Strategy
AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.
How AbbVie Inc. Makes Money
AbbVie earns revenue from global sales of prescription medicines and Allergan Aesthetics products. Its FY2025 portfolios were led by immunology at $30.406 billion, neuroscience at $10.767 billion, oncology at $6.655 billion, and aesthetics at $4.860 billion. The company funds internal research and supplements its pipeline through licensing and acquisitions.
AbbVie Acquisitions FAQ
What was AbbVie's largest acquisition?
AbbVie completed its acquisition of Allergan in May 2020, adding neuroscience, eye care, and aesthetics products.
Why did AbbVie acquire Pharmacyclics?
The 2015 acquisition added Imbruvica and expanded AbbVie's hematologic oncology business.
What did ImmunoGen add?
The 2024 acquisition added Elahere and antibody-drug conjugate programs in oncology.
What did Cerevel add?
The 2024 acquisition added clinical-stage neuroscience programs including emraclidine and tavapadon.
Why did AbbVie buy Allergan?
AbbVie acquired Allergan for $63 billion in 2019 to heavily diversify its revenue away from Humira, gaining the highly lucrative Botox franchise in the process.
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore AbbVie
Core profile pages, founders and related research hubs for this company.